The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:
1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.
Participants will:
1. Answer questions about their health and symptoms. 2. Give blood samples 3. Have lung function tests and other standard check-ups. 4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.
Age ≥18 years (≥40 years for COPD patients).
Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.
PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 <80% predicted)
Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.
Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.
Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.
Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)
Pregnant or lactating women.
6
Trial groupsSee each trial group below.